Brokerages expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will report earnings of ($0.25) per share for the current quarter, according to Zacks. Two analysts have provided estimates for Celldex Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.23). Celldex Therapeutics reported earnings per share of ($0.29) during the same quarter last year, which would suggest a positive year over year growth rate of 13.8%. The firm is scheduled to announce its next earnings results on Monday, November 6th.

According to Zacks, analysts expect that Celldex Therapeutics will report full-year earnings of ($1.06) per share for the current fiscal year, with EPS estimates ranging from ($1.12) to ($0.98). For the next year, analysts expect that the business will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.12) to ($0.82). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. The firm had revenue of $3.83 million for the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The business’s revenue for the quarter was up 175.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.32) EPS.

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, August 1st. Jefferies Group LLC restated a “hold” rating and issued a $3.50 price target (down previously from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, May 11th. Zacks Investment Research cut Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Aegis restated a “buy” rating on shares of Celldex Therapeutics in a research report on Thursday, June 29th. Finally, Cowen and Company restated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, June 6th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $7.32.

Shares of Celldex Therapeutics (NASDAQ CLDX) opened at 2.47 on Wednesday. Celldex Therapeutics has a one year low of $2.20 and a one year high of $5.02. The company’s market cap is $317.00 million. The firm has a 50-day moving average of $2.46 and a 200 day moving average of $2.99.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC boosted its position in Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 1,409 shares in the last quarter. Teachers Advisors LLC boosted its position in Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 1,433 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Celldex Therapeutics by 0.9% in the first quarter. Goldman Sachs Group Inc. now owns 280,425 shares of the biopharmaceutical company’s stock worth $1,012,000 after buying an additional 2,453 shares in the last quarter. Nationwide Fund Advisors boosted its position in Celldex Therapeutics by 3.5% in the second quarter. Nationwide Fund Advisors now owns 111,757 shares of the biopharmaceutical company’s stock worth $276,000 after buying an additional 3,742 shares in the last quarter. Finally, American International Group Inc. boosted its position in Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 3,880 shares in the last quarter. Hedge funds and other institutional investors own 63.88% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/16/0-25-earnings-per-share-expected-for-celldex-therapeutics-inc-cldx-this-quarter.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.